Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis
NCT01708603 · Bausch Health Americas, Inc. · PHASE3 · terminated · last registry update 2020-01-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Bausch Health Americas, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL12B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-05Results posted on the registry: Janssen Research & Development, LLC, Guselkumab + Placebo (NCT03158285)
- 2020-10-14Results posted on the registry: Janssen Research & Development, LLC, Guselkumab + Ustekinumab (NCT02319759)
- 2020-10-14Results posted on the registry: Janssen Research & Development, LLC, Guselkumab + Placebo (NCT03162796)
- 2020-09-25Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT03482011)
- 2020-08-24Phase 3 first posted: AbbVie, Risankizumab + Risankizumab (NCT04524611)
- 2020-08-10Phase 3 first posted: University of Miami, Advanced therapy only without dietary intervention (NCT04505410)
- 2020-07-28Results posted on the registry: Eli Lilly and Company, Ixekizumab + Guselkumab (NCT03573323)
- 2020-07-13Phase 3 first posted: Eli Lilly and Company, Mirikizumab IV + Mirikizumab SC (NCT04469062)
- 2020-06-30Phase 3 first posted: AbbVie, Risankizumab + Placebo (NCT04451720)
- 2020-06-18Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT02899988)
- 2020-06-17Phase 3 first posted: AbbVie, Risankizumab + Ustekinumab (NCT04435600)
- 2020-06-05Also stopped (withdrawn): Rockefeller University, Guselkumab (NCT04084665)
- 2020-05-29Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT02589665)
- 2020-05-21Phase 3 first posted: Janssen Pharmaceutical K.K., Guselkumab (NCT04397263)
- 2020-05-15Results posted on the registry: AstraZeneca, Brazikumab IV Infusion + Brazikumab SC Injection (NCT02574637)
- 2020-05-14Results posted on the registry: Janssen Pharmaceutical K.K., CNTO 1959 50 mg + CTNO 1959 100 mg (NCT02325219)
- 2020-04-24Results posted on the registry: AbbVie, Risankizumab 600 mg IV + Risankizumab 180 mg SC (NCT02513459)
- 2020-03-19Phase 3 first posted: Sun Pharmaceutical Industries Limited, TILD + matching placebo injections (NCT04314531)
- 2020-03-19Phase 3 first posted: Sun Pharmaceutical Industries Limited, TILD + matching placebo injections (NCT04314544)
- 2020-02-05Results posted on the registry: Anne Chang, Secukinumab (NCT03079531)
- 2020-01-18Phase 3 first posted: Eli Lilly and Company, Mirikizumab (NCT04232553)
- 2019-11-08Results posted on the registry: AbbVie, Risankizumab (NCT02203851)
- 2019-10-01Results posted on the registry: Janssen Research & Development, LLC, Guselkumab + Placebo (NCT03090100)
- 2019-09-25Phase 3 first posted: AbbVie, Risankizumab (NCT04102007)
- 2019-09-13Results posted on the registry: AbbVie, Fumaderm + risankizumab (NCT03255382)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision